<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Ana-Iris</forename><surname>Schiefer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Laura</forename><surname>Parlow</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<address>
									<settlement>CharitéeUniversitaetsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lisa</forename><surname>Gabler</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ildiko</forename><surname>Mesteri</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Neuropathology</orgName>
								<address>
									<settlement>Überlingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Oskar</forename><surname>Koperek</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Andreas</forename><surname>Von Deimling</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Institute of Pathology</orgName>
								<orgName type="department" key="dep2">Division of Oncology</orgName>
								<orgName type="laboratory">and Clinical Cooperation Unit Neuropathology, DKFZ and DKTK</orgName>
								<orgName type="institution">University of Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Berthold</forename><surname>Streubel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Matthias</forename><surname>Preusser</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Internal Medicine I</orgName>
								<orgName type="department" key="dep2">Comprehensive Cancer Center Vienna</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Annika</forename><surname>Lehmann</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<address>
									<settlement>CharitéeUniversitaetsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Udo</forename><surname>Kellner</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">Johannes Wesling Klinikum Minden</orgName>
								<address>
									<settlement>Minden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patrick</forename><surname>Pauwels</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Suzan</forename><surname>Lambin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Manfred</forename><surname>Dietel</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<address>
									<settlement>CharitéeUniversitaetsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Hummel</surname></persName>
							<email>michael.hummel@charite.de.</email>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<address>
									<settlement>CharitéeUniversitaetsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frederick</forename><surname>Klauschen</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<address>
									<settlement>CharitéeUniversitaetsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>M.D</roleName><forename type="first">Peter</forename><surname>Birner</surname></persName>
							<email>peter.birner@meduniwien.ac.at</email>
						</author>
						<author>
							<persName><forename type="first">Markus</forename><surname>Möbs</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<address>
									<settlement>CharitéeUniversitaetsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Departments of Pathology* and Obstetrics and Gynecology</orgName>
								<orgName type="institution">{ Medical University of Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Department of Pathology</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="institution">yy Antwerp University Hospital</orgName>
								<address>
									<settlement>Edegem</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Department of Pathology</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<addrLine>Währinger Gürtel 18-20</addrLine>
									<postCode>A-1090</postCode>
									<settlement>Vienna</settlement>
									<country>Austria, Austria; or</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Ph.D</orgName>
								<orgName type="department" key="dep2">Institute of Pathology</orgName>
								<orgName type="institution">Michael Hummel</orgName>
								<address>
									<addrLine>Charitéplatz 1</addrLine>
									<postCode>10117</postCode>
									<settlement>CharitéeUniversitätsmedizin Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="department">Department of Pathology (Medical</orgName>
								<orgName type="institution">University of Vienna</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">12AFF54248AF40845BF64EFD398A0F7D</idno>
					<idno type="DOI">10.1016/j.jmoldx.2015.12.005)</idno>
					<note type="submission">Accepted for publication December 9, 2015.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:28+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The mutated BRAF oncogene represents a therapeutic target in malignant melanoma.</s><s>Because BRAF mutations are also involved in the pathogenesis of other human malignancies, the use of specific BRAF inhibitors might also be extended to other diseases in the future.</s><s>A prerequisite for the clinical application of BRAF inhibitors is the reliable detection of activating BRAF mutations in routine histopathological samples.</s><s>In a multicenter approach, we evaluated a novel and fully automated PCR-based system (Idylla) capable of detecting BRAF V600 mutations in formalin-fixed, paraffin-embedded tissue within 90 minutes with high sensitivity.</s><s>We analyzed a total of 436 samples with the Idylla system.</s><s>Valid results were obtained in 421 cases (96.56%).</s><s>Its performance was compared with conventional methods (pyrosequencing or Sanger sequencing).</s><s>Concordant results were obtained in 406 cases (96.90%).</s><s>Reanalysis of eight discordant samples by next-generation sequencing and/or pyrosequencing with newly extracted DNA and the BRAF RGQ Kit confirmed the Idylla result in seven cases, resulting in an overall agreement of 98.57%.</s><s>In conclusion, the Idylla system is a highly reliable and sensitive platform for detection of BRAF V600 mutations in formalin-fixed, paraffin-embedded material, providing an efficient alternative to conventional diagnostic methods, particularly for routine diagnostics laboratories with limited experience in molecular pathology.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Within the past years, high-throughput molecular profiling of human tumors dramatically changed our understanding of cancer biology and has started to facilitate the stratification of patients for novel individualized therapy options: On the one hand, it is now clear that virtually all tumor entities are molecularly different, suggesting adapted treatment strategies.</s><s>On the other hand, treatment options that target molecular alterations (mainly somatic mutations) have been developed and show promising results. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref></s><s>Because of the molecular heterogeneity of the different tumors even within one entity, the application of mutation-specific treatment modalities requires molecular testing of tumor samples before initiation of therapy.</s><s>This facilitates the selection of specific therapies against a growing number of so-called actionable mutations.</s><s>Because only those patients whose tumors show the respective molecular alterations will benefit from a targeted treatment, there is a strong need for their reliable and fast detection.</s><s><ref type="bibr">3e5</ref> One prominent example in this context is the V600 (mostly V600E) mutation in the BRAF oncogene.</s><s>Almost all cases of hairy cell leukemia and approximately half of the cases of malignant melanoma and papillary thyroid carcinoma <ref type="bibr" target="#b5">6</ref> carry the V600E mutation.</s><s>In addition, BRAF V600 mutations are also detectable in a variety of other malignancies, although at a much lower frequency. <ref type="bibr" target="#b5">6</ref></s><s>Pharmacological agents capable of inhibiting mutated BRAF protein are potent pharmaceutical drugs, leading to an effective and rapid eradication of most melanoma cells harboring the V600E mutation.</s><s>Thus, several BRAF inhibitors have already received approval for use in standard patient care in metastatic melanoma.</s><s><ref type="bibr">7e9</ref> Therefore, mandatory testing for the presence of relevant BRAF mutations has reached routine diagnostics and is available in most established pathology departments.</s><s>However, sequencing and PCR-based techniques in routine formalin-fixed, paraffin-embedded (FFPE) specimens require a complex infrastructure, sophisticated preanalytics (with a variety of possible sources of errors), and highly skilled staff, and are therefore often not feasible in smaller pathological laboratories. <ref type="bibr" target="#b9">10</ref></s><s>n this study, we evaluated a novel, automated, sample-in, result-out, real-time PCRebased system (Idylla; Biocartis, Mechelen, Belgium) thatdon the basis of parts of this studydhas recently been CE-IVD certified for detection of BRAF mutations in FFPE material of various human malignancies.</s><s>The Idylla BRAF mutation test running on the Idylla system is designed to facilitate the detection of various V600 BRAF gene mutations in FFPE samples in approximately 90 minutes with a claimed sensitivity of 1% of mutated allele.</s><s>As a reference, a comparison with the results of established BRAF mutation detection methods was performed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient Samples and Study Design</head><p><s>All samples were derived from archived FFPE routine diagnostic material from Institutes of Pathology.</s><s>The use of these patient samples was approved by the respective local review boards and was in accordance with the Declaration of Helsinki.</s></p><p><s>The study was conducted at three different sites: UZA Antwerp (site A) included 39 melanoma samples, conducted the Idylla runs on those samples; Charité Berlin (site B) enrolled 209 samples of malignant melanoma, performed Idylla runs on these samples, and subjected all 248 samples from sites A and B to pyrosequencing (PS), which was regarded as the reference method.</s><s>From these 248 FFPE samples analyzed, 220 (88.7%) were metastatic tissue samples from malignant melanoma, most commonly lymph node metastases (122 samples, 49.2%), or from distant metastatic sites (98 samples, 39.5%).</s><s>Twenty-six samples (10.5%) were primary malignant melanomas, 18 (7.3%)</s><s>from the skin, 8 (3.2%) from other origins.</s><s>Localizations of two melanomas were not specified.</s><s>On the basis of visual assessment of hematoxylin and eosin (H&amp;E) staining of consecutive slides, all samples were enriched by manual macrodissection to reach a tumor cell content of at least 50%.</s><s>All Idylla runs and sequencing analyses were performed on the same tumor area of consecutive slides.</s></p><p><s>Medical University of Vienna (Vienna, Austria; site C) analyzed an additional 188 samples of various tumors (Table <ref type="table" target="#tab_0">1</ref>).</s><s>At this study site, Idylla results were compared with data obtained by Sanger sequencing (SaS).</s><s>Data on BRAF status obtained by SaS were already available in 157 tumor samples: 41 had been analyzed in previous studies, 11e13 and 116 had been analyzed for routine diagnostics in the International Organization for Standardizationecertified molecular pathology laboratory, Medical University of Vienna, and data were taken from reports.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mutation Detection by the Idylla Molecular Diagnostic System</head><p><s>The Biocartis molecular diagnostics platform (Idylla) is a novel, fully automated real-time PCR system.</s><s>It uses disposable cartridges with five independent PCR chambers that can simultaneously detect and quantify up to 30 molecular markers from a wide range of solid and liquid sample types, including blood, feces, and sputum, according to the manufacturer's description.</s></p><p><s>Using a mutation-specific amplification refractory mutation system primer, <ref type="bibr" target="#b13">14</ref> the Idylla BRAF assay is claimed to allow the identification of mutated alleles of as low as 1% allelic frequencies.</s></p><p><s>For the present study, a cartridge system was used, capable of detecting BRAF wild type (WT), BRAF V600E/ E2/D, or V600K/R/M mutations in three separate PCRs that are conducted in parallel from one sample.</s><s>Adequate DNA input/quality and successful PCR amplification are controlled by amplifying a reference sequence and a positive control, spotted in each PCR chamber, respectively.</s></p><p><s>Idylla analyses were performed according to the manufacturer's recommendations.</s><s>In brief, a tumor area of at least 25 mm 2 (for 10 mm slices) or 50 mm 2 (for 5 mm slices) per sample was transferred into the cartridges.</s><s>To achieve a tumor cell content of at least 50%, if appropriate, macrodissection on the basis of H&amp;E-stained slides was performed before further investigations.</s><s>All PS/SaS analyses were interpreted without knowledge of the results from the Idylla system, which does not give any scope for interpretation.</s></p><p><s>In addition, punch biopsy specimens from seven (five BRAF V600E and two BRAF WT at SaS) of the colorectal cancer (CRC) samples of the Vienna cohort were obtained after selection of tumor areas on H&amp;E slides using 1.5 mm inside diameter punch needles.</s><s>These punch biopsy specimens were transferred directly into the cartridges or put between two filter papers.</s><s>Of all seven cases, separate investigations using one, two, and three punch biopsy specimens per cartridge were performed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DNA Extraction and Sequencing</head><p><s>After deparaffinization with xylene, genomic DNA was extracted from macrodissected sections (5 to 10 mm thick) using the QIAamp DNA Mini Kit or the EZ1 DNA Tissue Kit 48 (both from Qiagen, Hilden, Germany), according to the manufacturer's recommendations.</s><s>For the further characterization of discordant cases, DNA extraction was performed with the Maxwell 16 FFPE Plus LEV DNA Purification Kit using the Maxwell 16 instrument (Promega, Mannheim, Germany).</s><s>DNA concentrations were measured with a Nanodrop ND1000 microspectrophotometer (Peqlab, Erlangen, Germany) or the Qubit dsDNA HS Assay Kit (for high-throughput sequencing analyses; Life Technologies, Darmstadt, Germany).</s></p><p><s>PS was performed using the therascreen BRAF Pyro Kit (Qiagen), according to the manufacturer's protocol, with a minor modification: instead of 10 ng of genomic DNA, only 1 ng was subjected to PCR amplification.</s><s>SaS of BRAF exon 15 was performed by capillary sequencing, as described previously. <ref type="bibr" target="#b10">11</ref></s><s>For three discordant SaS/Idylla cases, allele-specific PCR was performed using the Qiagen allele-specific BRAF RGQ PCR Kit, according to the manufacturer's instructions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Next-Generation Sequencing</head><p><s>Ion Torrent PGM Multiplex-PCRebased amplicon high-throughput sequencing (HTS) was performed using the Ion Torrent PGM system (Life Technologies), according to the manufacturer's recommendations.</s><s>Briefly, 10 ng of genomic double-stranded DNA was used for library construction with the Ion AmpliSeq Colon and Lung Cancer Panel version 2 and the Ion AmpliSeq Library Kit 2.0 (Life Technologies).</s><s>The library quantification was performed on the 7900HT qPCR System (Applied Biosystems, Darmstadt, Germany) using the Ion Library TaqMan Quantitation Kit (Life Technologies).</s><s>Emulsion PCR and subsequent enrichment were realized with the help of the OneTouch 2 system (Life Technologies).</s><s>For HTS, the 318v2 chip was used as recommended by the manufacturer.</s><s>Data were analyzed using the Torrent Suite Software version 4.2 (Life Technologies).</s><s>Sequencing was repeated until a mutation was detected or the cumulative number of aligned reads (coverage) at position V600 reached a minimum of 5000.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Illumina MiSeq</head><p><s>Targeted gene sequencing was conducted using the TruSeq Amplicon Cancer Panel (Illumina, San Diego, CA), according to the manufacturer's instructions, as described previously. <ref type="bibr" target="#b14">15</ref></s><s>Variant analysis was conducted with the CLC Genomics Workbench 7.5 (Qiagen).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Diagnostic Performance Calculations</head><p><s>Overall agreement (% total agreement), negative and positive agreement, was estimated together with a 90% two-sided CI on the basis of the Wilson score method <ref type="bibr" target="#b15">16</ref> at the dichotomous</s></p><formula xml:id="formula_0">1 (100%) V600E/E2 1 (100%) V600E/E2/D Meningioma (n Z 4) 0 0 Malignant glioma (n Z 1) 0 0</formula><p><s>PTC, papillary thyroid cancer; TSA, traditional serrated adenoma.</s></p><p><s>level, mutation detected versus no mutation detected.</s><s>Percentage overall agreement is defined as the proportion of concordant results against the sum of concordant and discordant results.</s></p><p><s>Positive agreement is defined as the proportion of the number of valid tests resulting in the detection of a mutation that are in concordance between the Idylla system and the validation method against the number of all mutations detected with the validation system.</s></p><p><s>Negative agreement is defined as the proportion of concordant validation tests without mutation against the number of all reference tests without mutation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Overall Performance of the Idylla System</head><p><s>Two-hundred forty-eight tumor samples were analyzed by a direct side-by-side comparison with Idylla and PS at study sites A and B. The Idylla system yielded evaluable results in 236 samples; 12 (4.8%)</s><s>ended up with the final Idylla result of insufficient DNA input.</s><s>In comparison, valid results were obtained in 243 cases by PS (invalid results, 2.1%).</s><s>Because the latter cases also failed in the Idylla system, valid, nonmissing results for both methods were obtained in 236 samples at study sites A and B. From the 188 tumor samples analyzed by Idylla and SaS at study site C, 185 delivered evaluable results by Idylla [3 (1.6%) revealed insufficient DNA input].</s><s>Two cases (1.1%) with valid Idylla results did not reveal a PCR product by SaS, resulting in 183 cases with technically valid results for both methods.</s><s>However, because most cases were retrospectively selected from the routine database and previous studies with already known BRAF status assessed by SaS, a comparison of the efficiency of Idylla and SaS cannot be given in this setting.</s></p><p><s>In total, from the 436 tumor samples tested with the Idylla system, evaluable results were obtained in 421 (96.56%).</s><s>Neither high melanin contentdwhich is a known PCR inhibitordnor a high amount of necrotic tissue or decalcification and the presence of bone fragments in hairy cell leukemia biopsy specimens seemed to interfere with successful amplification.</s><s>The age of tissue samples analyzed successfully by the Idylla system ranged from 6 weeks to 31 years (30 samples &gt;10 years old, among them one from 1983 and five from the 1990s), and no correlation was observed between sample age and mutation status (data not shown).</s><s>Only one single case with an invalid Idylla result was an old sample from 1988.</s></p><p><s>To figure out whether there is a correlation between a valid result and sample input in the Idylla system, an additional ministudy with a varying amount of sample input was performed.</s><s>Therefore, punch biopsy specimens of the seven CRC cases (Miltex, 1.5 to 3 mm depth, 1.5 mm diameter) were prepared, and three runs with increasing sample input were performed for each specimen.</s><s>In the first run, one punch biopsy per sample was inserted; in the second run, two were inserted; and in the third run, three were assessed in one cartridge.</s><s>All punch biopsy specimens (21 runs) delivered valid results, 17 at the first attempt, and the remaining 4 in a repeat run.</s><s>Two punch biopsy specimens (CRC cases 5 and 6) failed to deliver a result in the first run (CRC case 6 yielded insufficient DNA input, and CRC case 5 resulted in an error), the other two cases (CRC cases 2 and 4) failed with insufficient DNA input in the second run, where two biopsy specimens per sample had been inserted.</s><s>Runs with one and three punch biopsy specimens of CRC cases 2 and 4 were successful at the first attempt.</s><s>The reason for this initial failure is not clear.</s><s>Reruns with the same conditions and new biopsy specimens ended up with valid results.</s><s>All results were identical to those from a previous investigation with Idylla using larger full-slide specimens, as indicated above.</s></p><p><s>To investigate if the Idylla system also works in tiny biopsy specimens, from nine of the samples above (one BRAF WT and eight BRAF V600E), considerably &lt;50 mm 2 of tissue (20 to 30 mm 2 , 5 mm thick sections) was processed twice, yielding identical results compared with larger amounts of tissue.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comparison of Results</head><p><s>From the 419 samples with technically valid results for both the Idylla system and one other method, 406 showed identical mutation status (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Of these, 188 (46.3%) tested positive for BRAF V600E/E2/D and 18 (4.4%)</s><s>for V600K/R/M.</s><s>Among those cases, one sample had considerably &lt;5% allelic frequencies of mutated BRAF V600E, according to PS, reaching the limit of detection of this method (as stated by the manufacturer); therefore, PS had to be repeated for confirmation of the result.</s><s>Two hundred (49.2%) of cases showed no BRAF mutation.</s><s>In one sample, PS identified a V600G mutation and was reported as WT by the Idylla analysis.</s><s>This extremely rare mutation is not covered by the Idylla system.</s></p><p><s>For 12 cases (6 melanomas, 3 hairy cell leukemias, 2 papillary thyroid cancers, and 1 traditional serrated adenoma), the Idylla system reported a mutation (11 V600E/E2/ D and 1 V600K/R/M), whereas the other methods (5 PS and 7 SaS) revealed a WT result.</s></p><p><s>Therefore, the percentage of overall agreement between Idylla and PS was 97.5% (90% CI, 95.2%e98.7%), the percentage of positive concordance was 99.1% (90% CI, 95.9%e 99.8%), and the percentage of negative concordance was 96.1% (90% CI, 92.2%e98.1%).</s><s>SaS/Idylla showed an overall concordance of 96.2% (90% CI, 93.1%e97.90%),</s><s>a positive concordance of 100% (90% CI, 97.3%e100%), and a negative concordance of 91.6% (90% CI, 85.2%e95.4%).</s></p><p><s>When analyzing both reference methods together, the percentage of overall agreement was 96.9% (90% CI, 95.2%e98.0%), the positive concordance was 99.5% (90% CI, 97.9%e99.9%),</s><s>and the negative concordance was 94.3% (90% CI, 91.1%e96.4%).</s></p><p><s>Regarding the mutation-specific agreement, the percentage of positive agreement was 100% for both V600E/E2/D and V600K/R/M, respectively.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Further Analysis of Discordant Cases</head><p><s>To identify the reason(s) for discrepant results between the Idylla system and the results of PS, all five discordant melanoma cases from the Berlin/Antwerp cohort (four V600E/E2/D and one V600K/R/M with Idylla, all WT by PS) were subjected to further analysis.</s><s>All results are summarized in Table <ref type="table" target="#tab_1">2</ref>.</s><s>In case 4, reexamination of the prepared tumor tissue used for Idylla analysis (Antwerp) and PS analysis (Berlin) revealed that different areas had been used for macrodissection.</s><s>Reanalysis of the identical areas by PS and Idylla analysis resulted in concordant outcomes of both tests for the respective areas (two WT and two BRAF V600 mutation).</s></p><p><s>Cases 1, 2, 3, and 5 were deep-sequenced on two different HTS platforms, the Ion Torrent PGM system and the Illumina MiSeq platform.</s><s>As controls, we analyzed five WT cases and six mutated cases with allelic frequencies between 4.7% and 60.8%, according to PS (four V600E, one V600E2, one V600K, and one V600R) on the PGM system.</s><s>In all controls, PGM analysis confirmed the results obtained by the Idylla system and PS.</s></p><p><s>HTS of the four cases resulted in the detection of a V600 mutation in all cases on the PGM system, whereas case 2 (V600E on Idylla/PGM) and case 5 (V600M on Idylla/PGM) revealed a WT sequence on the MiSeq platform (Table <ref type="table" target="#tab_1">2</ref>).</s></p><p><s>Case 5, positively tested for a V600M mutation with Idylla and PGM, revealed a high number of low-level C&gt;T/G&gt;A substitutions on both platforms that were not present in the other samples.</s></p><p><s>As a final approach and to exclude artifacts because of DNA fragmentation or fixation, we subjected freshly extracted DNA of the cases 1, 2, 3, and 4 with a potential V600E mutation to reanalysis by PS anddas the V600M mutation is caused by a C&gt;T substitution and C&gt;T conversions are wellknown artifacts in FFPE tissues <ref type="bibr" target="#b16">17</ref> dcase 5 with the potential V600M mutation was reanalyzed by HTS on the PGM system after treatment of DNA with uracil DNA glycosylase.</s><s>This has been reported to reduce false-positive HTS results caused by fixation artifacts. <ref type="bibr" target="#b16">17</ref></s><s>As a result, we were able to confirm BRAF V600E mutations in cases 1, 2, and 3, whereas case 5 with a potential V600M mutation was now also negative (WT) in the PGM analysis.</s></p><p><s>Three cases of discordant SaS/Idylla results (hairy cell leukemia: SaS, three WT; Idylla, three V600E/E2/D) were further analyzed by an allele-specific BRAF V600 kit, where V600E was detected.</s><s>Further evaluation of the H&amp;E-stained slides of the remaining discordant cases (two papillary thyroid cancers, one traditional serrated adenoma, and one melanoma brain metastasis) from the Vienna cohort showed that the amount of tumor cells was low (&lt;100 tumor cells), and the number of mutated cells might, therefore, have been lower than the detection limit of SaS.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Mutations in the BRAF oncogene are of increasing relevance in clinical oncology. <ref type="bibr" target="#b17">18</ref></s><s>These mutations are observed in a variety of human malignancies, and the vast majority of cases demonstrate a T1799A point mutation leading to V600E amino acid substitution. <ref type="bibr" target="#b17">18</ref></s><s>This mutation causes a constitutive activation of the BRAF serine/threonine kinase and activation of the mitogen-activated protein kinase cascade. <ref type="bibr" target="#b17">18</ref></s><s>In addition, V600E-mutated BRAF protein also leads to higher expression of matrix metalloproteases and to increased tumor cell motility. <ref type="bibr" target="#b18">19</ref></s><s>he constitutive kinase activity of the mutated BRAF protein can be inhibited pharmacologically, <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b20">21</ref> and BRAF inhibitors are approved for treatment of metastatic melanoma. <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b21">22</ref></s><s>The successful treatment with BRAF inhibitors in other cancers is currently tested in clinical trials, <ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b23">24</ref> although the efficacy of BRAF inhibition appears to differ among cancer types because CRCs with the BRAF V600E mutation are irresponsive to inhibition. <ref type="bibr" target="#b24">25</ref></s><s> prerequisite for BRAF inhibitory therapy is the diagnosis of BRAF mutations in histological routine samples.</s><s>A variety of methods are available for the detection of BRAF mutations, including SaS, <ref type="bibr" target="#b17">18</ref> PS, <ref type="bibr" target="#b9">10</ref> and next-generation sequencing <ref type="bibr" target="#b25">26</ref> techniques and various PCR-based methods.</s><s><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b27">28</ref> All these methods have in common that they require expensive infrastructure and highly skilled staff to perform analyses and interpretation of results.</s><s>In addition, the need for isolation of DNA from FFPE material before analysis is a further timeand resource-consuming, as well as a variability-inducing step, with increased risk for sample-to-sample crosscontamination.</s><s>Therefore, the detection of gene mutations at the DNA level is not suitable for pathology laboratories without molecular diagnostic units, resulting in the need to send these specimens to other facilities, generating further delay.</s><s>The detection of BRAF mutations by immunohistochemistry is not able to solve the problem because only V600E mutations are detectable.</s><s>Immunohistochemical staining for BRAF protein represents a quick low-technology screening method and is able to detect mutated BRAF protein even in single tumor cells, but its main disadvantage is the fact that only V600E mutations are covered.</s><s><ref type="bibr" target="#b29">29</ref> So, in cases with negative immunohistochemical results, it cannot be excluded that other types of V600 mutation are present.</s><s><ref type="bibr">12,13,30e33</ref> So, a strong need for quick, easy-to-handle, and reliable methods for detection of BRAF mutations in routine pathology exists, especially in laboratories without specific molecular pathology infrastructure and know-how.</s></p><p><s>The Idylla system tested in this study has recently been CE-IVD certified for detection of BRAF mutations in malignant melanoma, and this CE-IVD certification was based on parts of our study.</s><s>Currently, only data from a small pilot study using the Idylla system for detection of BRAF mutations exist. <ref type="bibr" target="#b34">34</ref></s><s>In this recently published study, the Idylla BRAF Mutation test was compared with cobas 4800 BRAF V600 Mutation Test, MiSeq deep sequencing, and PCR-based sequencing, mass spectrometric detection, or next-generation sequencing.</s></p><p><s>The authors found agreement results comparable to ours.</s><s>However, this study investigated a much smaller sample number (58 and 100) with other reference methods and was conducted on an early prototype of the Idylla system, not on the commercially available system, as in our study.</s></p><p><s>The complete processing time for sample preparation, PCR, and reporting is &lt;90 minutes, with &lt;2 minutes hands-on time per sample, which allows for a timely reporting.</s></p><p><s>Because the FFPE tissue sections can be directly put into the cartridges, no separate DNA extraction step must be performed.</s><s>In our study, the Idylla system yielded results identical to other methods for BRAF mutation detection in the vast majority of cases, regardless of tumor type and sample age.</s><s>Except for one single case with a V600G mutation, which is rare and not covered by the Idylla system, all mutations detected with the other methods were also found by Idylla, even in a case with considerably &lt;5% allelic frequency of a mutated BRAF allele.</s><s>Furthermore, Idylla identified an additional 12 BRAF mutated cases that were not detected by the other methods.</s><s>Further analysis of five of these discrepant cases by HTS and PS with DNA extracted by different methods confirmed the Idylla result (BRAF V600E/E2/D) in four cases, whereas in one case (V600K/R/M) the Idylla system most probably produced a false-positive result because of fixation artifacts.</s><s>The three discordant hairy cell leukemia cases revealed a BRAF V600E mutation and confirmed the Idylla result when tested with a more sensitive allele-specific BRAF V600 test.</s><s>The Idylla system also worked in small biopsy specimens with only 20 mm 2 tumor tissues.</s></p><p><s>These results confirm the high sensitivity and specificity of the Idylla system and its ability to deal with samples of low DNA quality and low tumor cell content.</s><s>This high sensitivity also explains the detection of BRAF mutations in four discrepant cases, where the other method applied failed to identify these mutations because of low tumor cell contents.</s><s>However, the Idylla system provides no information regarding the allelic frequency of the detected BRAF mutations.</s><s>This might be of disadvantage in cases where only a fraction of tumor cells carry the BRAF mutation in which alternative treatment options appear to be relevant.</s><s>In contrast to KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors, <ref type="bibr">12,13,30e33,35</ref> clinical information regarding the efficacy of BRAF inhibition in patients with low BRAF mutation frequency tumors is still not available.</s></p><p><s>Compared with PS, the requirement for repeated analyses was comparable, and dropout rates were a little bit higher with the Idylla system (4.8% versus 2.1%).</s><s>Even though the manufacturer recommends only the use of FFPE material with a maximum age of 10 years, PCR failures in our study were neither associated with age of blocks nor with high amounts of melanin, presence of decalcified bone fragments, or extended areas of necrotic tissue.</s><s>All in all, the Idylla system was able to correctly identify the BRAF status in a higher number of samples than PS or SaS, reaching a sensitivity that can otherwise only be achieved with laborand cost-intensive HTS techniques.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>The Idylla system is a highly reliable and sensitive platform for detection of BRAF mutations in routine diagnostic FFPE material of a variety of human tumor tissues.</s><s>An additional major advantage of this system is the extremely simple usability, which requires no specific infrastructure and delivers results in only approximately 90 minutes.</s><s>Thus, the Idylla system might be of special interest for diagnostic units without molecular expertise and infrastructural environment.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Results of Mutation Detection by Routine Diagnostic Methods and Idylla System for Samples with Valid Results for Both Methods</s></p></div></figDesc><table><row><cell></cell><cell>BRAFmut at Sanger</cell><cell></cell><cell></cell></row><row><cell></cell><cell>sequencing or</cell><cell></cell><cell></cell></row><row><cell>Entity</cell><cell>pyrosequencing</cell><cell>BRAFmut at Idylla</cell><cell>Comments</cell></row><row><cell>Malignant melanoma (all study sites)</cell><cell>101 (39.5%) V600E/E2</cell><cell>106 (41.4%) V600E/E2/D</cell><cell></cell></row><row><cell>(n Z 256)</cell><cell>16 (6.3%) V600K</cell><cell>19 (7.4%) V600K/R/M</cell><cell></cell></row><row><cell></cell><cell>2 (0.8%) V600R</cell><cell></cell><cell></cell></row><row><cell></cell><cell>1 (0.4%) V600G</cell><cell></cell><cell></cell></row><row><cell>PTC (n Z 59)</cell><cell>29 (49.3%) V600E/E2</cell><cell>31 (52.5%) V600E/E2/D</cell><cell>Few tumor cells in the two</cell></row><row><cell></cell><cell></cell><cell></cell><cell>divergent cases</cell></row><row><cell>Hairy cell leukemia and hairy cell</cell><cell>17 (73.9%) V600E/E2</cell><cell>21 (91.3%) V600E/E2/D</cell><cell>V600E in the three discordant</cell></row><row><cell>variant (n Z 23)</cell><cell></cell><cell></cell><cell>cases when tested with the</cell></row><row><cell></cell><cell></cell><cell></cell><cell>allele-specific BRAF V600 kit</cell></row><row><cell>Colorectal cancer (n Z 52)</cell><cell>24 (46.4%) V600E/E2</cell><cell>24 (46.4%) V600E/E2/D</cell><cell></cell></row><row><cell>Glioblastoma (n Z 4)</cell><cell>3 (75%) V600E/E2</cell><cell>3 (75%) V600E/E2/D</cell><cell></cell></row><row><cell>Ovarian cancer (n Z 5)</cell><cell>3 (60%) V600E/E2</cell><cell>3 (60%) V600E/E2/D</cell><cell></cell></row><row><cell>Sessile serrated adenoma/polyp</cell><cell>4 (100%) V600E/E2</cell><cell>4 (100%) V600E/E2/D</cell><cell></cell></row><row><cell>(n Z 4)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>TSA (n Z 2)</cell><cell>1 (50%) V600E/E2</cell><cell>2 (100%) V600E/E2/D</cell><cell>Only few TSA cells</cell></row><row><cell>Tubulary adenoma (n Z 2)</cell><cell>1 (50%) V600E/E2</cell><cell>1 (50%) V600E/E2/D</cell><cell></cell></row><row><cell>Craniopharyngioma (n Z 3)</cell><cell>2 (66.7%) V600E/E2</cell><cell>2 (66.7%) V600E/E2/D</cell><cell></cell></row><row><cell>Anaplastic xanthoastrocytoma (n Z 1)</cell><cell>1 (100%) V600E/E2</cell><cell>1 (100%) V600E/E2/D</cell><cell></cell></row><row><cell>Pilozytic astrocytoma (n Z 2)</cell><cell>1 (50%) V600E/E2</cell><cell>1 (50%) V600E/E2/D</cell><cell></cell></row><row><cell>Pleomorphic xanthoastrocytoma</cell><cell></cell><cell></cell><cell></cell></row><row><cell>(n Z 1)</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Results of Reassessment of Discordant Cases (Berlin/Antwep Cohort) Fresh DNA extraction from newly prepared slides with Maxwell DNA-extraction system.</s><s>ND, not performed; PS, pyrosequencing; UDG, uracil DNA glycosylase; WT, wild type.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>PGM</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>PS after</cell><cell>after</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Maxwell DNA</cell><cell>UDG</cell><cell></cell></row><row><cell cols="2">Case PS Idylla</cell><cell>PGM</cell><cell>MiSeq</cell><cell>extraction</cell><cell cols="2">treatment Comments</cell><cell>Conclusion</cell></row><row><cell>1</cell><cell cols="2">WT V600E/E2/D V600E</cell><cell>V600E</cell><cell cols="2">V600E (62.6%) y ND</cell><cell>High DNA fragmentation</cell><cell>Mutation</cell></row><row><cell></cell><cell></cell><cell>(43.1%)*</cell><cell>(31.8%)*</cell><cell></cell><cell></cell><cell>High number of additional DNA</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>variations in other genes (PGM)</cell></row><row><cell>2</cell><cell cols="2">WT V600E/E2/D V600E</cell><cell>WT*</cell><cell cols="2">V600E (25.4%)* ND</cell><cell>High DNA fragmentation</cell><cell>Mutation</cell></row><row><cell></cell><cell></cell><cell>(6.2%)*</cell><cell></cell><cell></cell><cell></cell><cell>High number of additional DNA</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>variations in other genes (PGM)</cell></row><row><cell>3</cell><cell cols="2">WT V600E/E2/D V600E</cell><cell>V600E</cell><cell cols="2">V600E (3.8%)* ND</cell><cell></cell><cell>Mutation</cell></row><row><cell></cell><cell></cell><cell>(3.4%)</cell><cell>(5.0%)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>4</cell><cell cols="2">WT V600E/E2/D WT</cell><cell>ND</cell><cell cols="2">V600E (7.7%)* ND</cell><cell>Different tumor area used for</cell><cell>Mutation/WT</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>macrodissection between Idylla</cell><cell>(concordance</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>and PS þ PGM</cell><cell>between Idylla</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>and PS in both</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>tumor areas</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>analyzed)</cell></row><row><cell>5</cell><cell cols="2">WT V600K/R/M V600M</cell><cell>WT</cell><cell>ND</cell><cell>WT*</cell><cell>High numbers of low level C&gt;T/G&gt;A</cell><cell>WT</cell></row><row><cell></cell><cell></cell><cell>(2.3%)</cell><cell></cell><cell></cell><cell></cell><cell>conversions (PGM/MiSeq)</cell></row><row><cell></cell><cell cols="5">*Fresh DNA extraction from consecutive slides with Maxwell DNA-extraction system.</cell><cell></cell></row></table><note><p><s>y</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">The Journal of Molecular Diagnosticsjmd.amjpathol.org</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">jmd.amjpathol.org -The Journal of Molecular Diagnostics</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>A.-I.S., L.P., L.G., I.M., O.K., A.v.D., B.S., M.P., A.L., U.K., P.P., S.L., and F.K. collected and interpreted data, and wrote and approved the manuscript; M.D., P.B., M.H., and M.M. conceived and designed the experiments, and wrote the manuscript; P.B. is the guarantor of this work and takes responsibility for the integrity of the data and the accuracy of the data analysis.</s></p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Personalized oncology: genomic screening in phase 1</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">V</forename><surname>Tuxen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jonson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Santoni-Rugiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Hasselby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Lassen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">APMIS</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="723" to="e733" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Precision therapy for lymphoma: current state and future directions</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Intlekofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Younes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="585" to="e596" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The melanoma revolution: from UV carcinogenesis to a new era in therapeutics</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Lo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Fisher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="page" from="945" to="e949" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a metaanalysis of randomized, controlled trials</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Sorich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Wiese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rowland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kichenadasse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Mckinnon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Karapetis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="13" to="e21" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">implications for targeted therapies in metastatic colorectal cancer</title>
		<author>
			<persName><forename type="first">W</forename><surname>De Roock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Vriendt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Normanno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ciardiello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tejpar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S:</forename><surname>Kras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pik3ca</forename><surname>Braf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="594" to="e603" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Kudchadkar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Control</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="221" to="e230" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Advances in personalized medicine: medicinal chemistry and pharmacology of vemurafenib and ivacaftor</title>
		<author>
			<persName><forename type="first">M</forename><surname>Pellowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Merk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schubert-Zsilavecz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmazie</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="484" to="e491" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation</title>
		<author>
			<persName><forename type="first">G</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Mckee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Ning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hazarika</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Theoret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">C</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sridhara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Roscoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Mcguinn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Helms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Miksinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Zirkelbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Earp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ibrahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Justice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pazdur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="4994" to="e5000" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Falchook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kurzrock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Arkenau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hamid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Infante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Millward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Pavlick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>O'day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Blackman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lebowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ouellet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Kefford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">379</biblScope>
			<biblScope unit="page" from="1893" to="e1901" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma</title>
		<author>
			<persName><forename type="first">C</forename><surname>Spittle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Nathanson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Gimotty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rappaport</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Brose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Medina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Letrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Herlyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Edwards</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Mol Diagn</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="464" to="e471" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma</title>
		<author>
			<persName><forename type="first">O</forename><surname>Koperek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kornauth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Capper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Berghoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Asari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Niederle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Von Deimling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Birner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Preusser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg Pathol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="844" to="e850" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E</title>
		<author>
			<persName><forename type="first">I</forename><surname>Mesteri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Capper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Schoppmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Von Deimling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Birner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mod Pathol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="135" to="e144" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Expression of BRAF V600E mutant protein in epithelial ovarian tumors</title>
		<author>
			<persName><forename type="first">M</forename><surname>Preusser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Capper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Berghoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Horvat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wrba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schindl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Schoppmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Von Deimling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Birner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Appl Immunohistochem Mol Morphol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="159" to="e164" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Newton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Heptinstall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Powell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Summers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kalsheker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Markham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="2503" to="e2516" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Validation of a next-generationsequencing cancer panel for use in the clinical laboratory</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Simen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Goswami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">O</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bajaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Z</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Peiper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">X</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Pathol Lab Med</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="508" to="e517" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Interval estimation for the difference between independent proportions: comparison of eleven methods</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Newcombe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="873" to="e890" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase</title>
		<author>
			<persName><forename type="first">H</forename><surname>Do</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dobrovic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="546" to="e558" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Mutations of the BRAF gene in human cancer</title>
		<author>
			<persName><forename type="first">H</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Bignell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stephens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Edkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Clegg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">417</biblScope>
			<biblScope unit="page" from="949" to="e954" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling</title>
		<author>
			<persName><forename type="first">C</forename><surname>Mesa</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mirza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mitsutake</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sartor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Medvedovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tomlinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Knauf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Fagin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="6521" to="e6529" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Cabanillas ME: Efficacy and tolerability of vemurafenib in patients with BRAF-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience</title>
		<author>
			<persName><forename type="first">R</forename><surname>Dadu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Busaidy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Waguespack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Habra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Ying</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bassett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jimenez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Sherman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="E77" to="E81" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent anti-leukemic activity</title>
		<author>
			<persName><forename type="first">V</forename><surname>Pettirossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Santi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Imperi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Russo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pucciarini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bigerna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schiavoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fortini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Spanhol-Rosseto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sportoletti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mannucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Martelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Klein-Hitpass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Falini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tiacci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="1207" to="e1216" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hauschild</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Robert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Haanen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ascierto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Larkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dummer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Garbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Testori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hogg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lorigan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lebbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jouary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schadendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ribas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>O'day</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Sosman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kirkwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Eggermont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nolop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Flaherty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Mcarthur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="2507" to="e2516" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Hairy cell leukemia: new genes, new targets</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Kreitman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Hematol Malig Rep</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="184" to="e195" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Cabanillas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Lazar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Sanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Ilagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nolop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Sherman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thyroid</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1277" to="e1283" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR</title>
		<author>
			<persName><forename type="first">A</forename><surname>Prahallad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Nicolantonio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Salazar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zecchin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Beijersbergen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Bardelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bernards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">483</biblScope>
			<biblScope unit="page" from="100" to="e103" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Clinical mutation panel testing by next-generation sequencing in advanced melanoma</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Siroy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Boland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Milton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Roszik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Frankian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Malke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="508" to="e515" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lade-Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Romer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Guldberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Riber-Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Steiniche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Kristensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Mol Diagn</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="70" to="e80" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Bloom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">U</forename><surname>Vallera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rueschoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Meldrum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schilling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kovach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ochoa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Langland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Halait</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dugan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Pathol Lab Med</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="1385" to="e1391" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody</title>
		<author>
			<persName><forename type="first">D</forename><surname>Capper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Preusser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Habel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sahm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Ackermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schindler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pusch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mechtersheimer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zentgraf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Von Deimling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="11" to="e19" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Li</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Clin Exp Pathol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="4323" to="e4328" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma</title>
		<author>
			<persName><forename type="first">K</forename><surname>Dvorak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Aggeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Palting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mckelvie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ruszkiewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Waring</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pathology</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="509" to="e517" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Hayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Takeshita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nishikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nishikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Arakawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yamashita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sugiura-Ogasawara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol Rep</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1815" to="e1819" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Ida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Vrana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Jentoft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Caron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Jenkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Giannini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol Commun</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">20</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<author>
			<persName><forename type="first">F</forename><surname>Janku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Claes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Falchook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Devogelaere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kockx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">V</forename><surname>Bempt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reijans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Naing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Piha-Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">R</forename><surname>Holley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Tsimberidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Stepanek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Kopetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Subbiah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Wheler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Zinner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Karp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Luthra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Roy-Chowdhuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sablon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Meric-Bernstam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Maertens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kurzrock</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">BRAF mutation testing with a rapid, fully integrated molecular diagnostics system</title>
				<imprint>
			<date type="published" when="2015">2015</date>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="26886" to="e26894" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones</title>
		<author>
			<persName><forename type="first">A</forename><surname>Marchetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Milella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Felicioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cappuzzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Irtelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Grammastro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sciarrotta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Malatesta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nuzzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Finocchiaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Perrucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Carlone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gelibter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Ceribelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mezzetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Iacobelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cognetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Buttitta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neoplasia</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1084" to="e1092" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
